Wealth Alliance’s Moderna MRNA Stock Holding History

Wealth Alliance’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,432	Closed	-$220K	–	523
2023 Q1	$220K	Buy	+1,432	New	+$236K	0.04%	453

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Wealth Alliance's MRNA Position: Q2 2023 in Review

Wealth Alliance sold out of Moderna (MRNA) in Q2 2023, closing a stake of 1,432 shares — an estimated $220K sold.

Wealth Alliance first reported a position in MRNA in Q1 2023 and held it in 1 quarter. The position peaked at $220K in Q1 2023. 965 funds tracked by Wall St. Rank hold MRNA as of Q2 2023.

Wealth Alliance reported no remaining Moderna position as of Q2 2023 after selling out during the quarter.
Wealth Alliance sold 1,432 Moderna shares in Q2 2023, an estimated $220K.
Wealth Alliance first reported a position in Moderna in Q1 2023 and held it in 1 quarter.
Wealth Alliance's Moderna position peaked at $220K in Q1 2023.
965 funds tracked by Wall St. Rank held Moderna as of Q2 2023.

Based on Wealth Alliance's 13F filing for Q2 2023, filed 2 Aug 2023.